Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Dermatomyositis: early-phase trial registry
12 of 20 indexed Dermatomyositis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #848 of 28,707 conditions by registered trial count.
20 US clinical trials · 12 currently recruiting · #848 of 28,707 conditions by registered trial count
Dermatomyositis: 20 US clinical trials tracked, 12 recruiting.
Dermatomyositis is the subject of 20 registered US clinical trials on ClinicalTrials.gov, 12 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most active sponsor is argenx, running 2 of these trials.
Enrollment posture brief
Registry condition dermatomyositis
OPEN 12 | RECR 60% | LATE 3 | EARLY 11 | RANK #848 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abuse, Drug (60% recruiting · 5 trials)
Dermatomyositis lists 12 open slots (60% of 20 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Dermatomyositis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Dermatomyositis is recruiting above its size-band peers.
12 of 20 indexed trials (60%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Dermatomyositis trials is spread across many organizations.
argenx accounts for 2 of 20 trials (10%). 17 distinct sponsors appear on at least one study for this condition label.
-
Typical Dermatomyositis enrolment sits around 95 participants.
Median target enrolment is 95 among the 20 trials that report a genuine target (sentinel values excluded). 11 of those (55%) plan for fewer than 100 participants.
-
Dermatomyositis research is mostly interventional.
14 interventional and 6 observational studies make up this index (70% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
20 total, page 1 of 1
Rheumatology Patient Registry and Biorepository
Yale University
NCT04402086
Adult and Juvenile Myositis
National Institute of Environmental Health Sciences (NIEHS)
NCT00017914
MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)
Myositis International Health & Research Collaborative Alliance Foundation
NCT07374107
Environmental Risk Factors for the Anti-synthetase Syndrome
National Institute of Environmental Health Sciences (NIEHS)
NCT01276470
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
National Cancer Institute (NCI)
NCT03816345
Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
University of Pennsylvania
NCT02945345
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
Pfizer
NCT06698796
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Cabaletta Bio
NCT06154252
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Kyverna Therapeutics
NCT07403188
Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis
Stanford University
NCT06298019
Intralesional Injection of STS in Treatment of Calcinosis
Robyn T. Domsic, MD, MPH
NCT06672822
Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis
The Cleveland Clinic
NCT06857240
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
argenx
NCT05523167
A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis
Priovant Therapeutics
NCT05437263
A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis
Galapagos
NCT05695950
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
argenx
NCT06284954
Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)
Octapharma
NCT02728752
Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
Chester Oddis
NCT02043548
An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study
Pfizer
NCT05192200
Methimazole to Treat Polymyositis and Dermatomyositis
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NCT00001421
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 9 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Dermatomyositis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Dermatomyositis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Dermatomyositis page
20 registered trials, 12 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 12 Dermatomyositis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- argenx sponsors the most Dermatomyositis trials on record, review their full trial history before evaluating a specific study. See argenx's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Dermatomyositis condition card totals 20 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.